This menu provides the list of EV miRNAs identified by high-throughput analyses.
Refresh all contents
Search:
Dataset accession
miRBase accession
Mature name
Orthologous group
Superdomain:
All
Prokaryote
Eukaryote
Filter datasets:
- "Sample type" indicates the source from which EVs originated (e.g. B cell, serum).
- "Sample status" indicates the condition of the source from which EVs originated (e.g. Normal, miR-146a-treated, Patients of hernia).
By species
Homo sapiens
Mus musculus
In vitro/In vivo
Ex vivo
In vitro
In vivo
By sample type
B cell (Raji)
Blood
Bone marrow stromal cells
Bone marrow-derived mesenchymal stem cell (R14)
Breast cancer cells (4T1)
Breast cancer cells (MCF7)
Breast cancer cells (MDA-MB-231)
Colon cancer cell (HCT116)
Colon cancer cell (HT29)
Colon cancer cell (RKO)
Colon cancer cell (SW48)
Colorectal cancer cell (SW480)
Colorectal cancer cell (SW620)
Gastric cancer cells (SGC-7901)
Leukemia cell (K562)
Liver cancer cells (CSQT-2)
Liver cancer cells (HCC-LM3)
Liver cancer cells (HepG2)
Liver cancer cells (MHCC-97L)
Lung cancer cell (DMS563)
Lung cancer cell (NCI_H69)
Lung cancer cell (SBC-3)
Mammary gland cells (MCF10A)
Mammary gland cells (NMuMG)
Mast cell (HMC-1)
Metastatic gastric cacncer cell (AZP7a)
Metastatic gastric cancer cell (AZ521)
Multiple myeloma cells (KMS-11)
Multiple myeloma cells (RPMI8226)
Multiple myeloma cells (U266)
Oral cancer cells (HOC313-LM)
Oral cancer cells (HOC313-P)
Plasma
Primary dendritic cell
Seminal plasma
Serum
T cell (Jurkat)
By sample status
24 hr culture
72 hr culture
Colorectal cancer_stage2
Colorectal cancer_stage3a
Colorectal cancer_stage3b
Colorectal cancer_stage4
Electroporated with Dicer antibody
Extremely severe hand, foot, and mouth disease
Healthy_timepoint1
Healthy_timepoint2
High density
Hypoxic condition (24 hr)
Mild hand, foot, and mouth disease
Multiple myeloma patients
Normal
Normal_Agilent
Normal_Exiqon
Normal_old
Omeprazole-treated
Pancreatic cancer patient_Exiqon
Pollen allergy_timepoint1
Survived under long-term hypoxia
Transplant islets into mouse xenotransplantation-rejected
Type 1 diabetes
shDicer-transfected
Maximum false positive rate (FPR):
Maximum true positive rate (TPR):
- FPR is the probability that an absent miRNA accidently have higher intensity than that miRNA.
- TPR is the percentile of miRNA among the present miRNAs.
Please see user manual in the contact us/help menu for detail.
Number of molecules in one page:
100
200
All
The downloaded CSV file is not exactly the same as the displayed table. Opening CSV file with Excel can impair its content.
Since there are multiple primers in the microarray, the same miRNA can have several FPR and TPR values.
Mature name
miRBase accession
FPR
TPR
Publication
Orthologous group
Identification count
All / Prokaryote / Eukaryote
(FPR<0.05,TPR<0.5)
hsa-miR-509-3-5p
MIMAT0004975
1.8e-2
1.8e-2
Replenishing exosomes from older bone marrow stromal cells with miR-340 inhibits myeloma-related angiogenesis.
Blood Adv. 2017 May 16;1(13):812-823. doi: 10.1182/bloodadvances.2016003251. eCollection 2017 May 23.
MIPF0000130_1
65
/
0
/
65
hsa-miR-509-5p
MIMAT0004779
1.8e-2
1.8e-2
Replenishing exosomes from older bone marrow stromal cells with miR-340 inhibits myeloma-related angiogenesis.
Blood Adv. 2017 May 16;1(13):812-823. doi: 10.1182/bloodadvances.2016003251. eCollection 2017 May 23.
MIPF0000130_1
65
/
0
/
65
hsa-miR-510-5p
MIMAT0002882
1.8e-2
1.8e-2
Replenishing exosomes from older bone marrow stromal cells with miR-340 inhibits myeloma-related angiogenesis.
Blood Adv. 2017 May 16;1(13):812-823. doi: 10.1182/bloodadvances.2016003251. eCollection 2017 May 23.
MIPF0000130_1
65
/
0
/
65
hsa-miR-512-5p
MIMAT0002822
1.8e-2
1.8e-2
Replenishing exosomes from older bone marrow stromal cells with miR-340 inhibits myeloma-related angiogenesis.
Blood Adv. 2017 May 16;1(13):812-823. doi: 10.1182/bloodadvances.2016003251. eCollection 2017 May 23.
MIPF0000130_1
65
/
0
/
65
hsa-miR-513a-5p
MIMAT0002877
1.8e-2
1.8e-2
Replenishing exosomes from older bone marrow stromal cells with miR-340 inhibits myeloma-related angiogenesis.
Blood Adv. 2017 May 16;1(13):812-823. doi: 10.1182/bloodadvances.2016003251. eCollection 2017 May 23.
MIPF0000130_1
65
/
0
/
65
hsa-miR-513a-5p
MIMAT0002877
0.0e+0
7.9e-2
Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer.
Nat Commun. 2018 Jan 15;9(1):191. doi: 10.1038/s41467-017-02583-0.
MIPF0000130_1
65
/
0
/
65
hsa-miR-513a-5p
MIMAT0002877
0.0e+0
9.6e-2
Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer.
Nat Commun. 2018 Jan 15;9(1):191. doi: 10.1038/s41467-017-02583-0.
MIPF0000130_1
65
/
0
/
65
hsa-miR-513b-5p
MIMAT0005788
0.0e+0
2.0e-1
Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer.
Nat Commun. 2018 Jan 15;9(1):191. doi: 10.1038/s41467-017-02583-0.
MIPF0000130_1
65
/
0
/
65
hsa-miR-513c-5p
MIMAT0005789
0.0e+0
2.6e-1
Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer.
Nat Commun. 2018 Jan 15;9(1):191. doi: 10.1038/s41467-017-02583-0.
MIPF0000130_1
65
/
0
/
65
hsa-miR-514b-5p
MIMAT0015087
0.0e+0
2.3e-1
Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer.
Nat Commun. 2018 Jan 15;9(1):191. doi: 10.1038/s41467-017-02583-0.
MIPF0000130_1
65
/
0
/
65
hsa-miR-513a-5p
MIMAT0002877
4.3e-3
4.3e-3
Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer.
Nat Commun. 2018 Jan 15;9(1):191. doi: 10.1038/s41467-017-02583-0.
MIPF0000130_1
65
/
0
/
65
hsa-miR-514b-5p
MIMAT0015087
2.8e-2
2.8e-2
Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer.
Nat Commun. 2018 Jan 15;9(1):191. doi: 10.1038/s41467-017-02583-0.
MIPF0000130_1
65
/
0
/
65
hsa-miR-508-5p
MIMAT0004778
4.9e-2
4.9e-2
Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer.
Nat Commun. 2018 Jan 15;9(1):191. doi: 10.1038/s41467-017-02583-0.
MIPF0000130_1
65
/
0
/
65
hsa-miR-513b-5p
MIMAT0005788
4.9e-2
4.9e-2
Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer.
Nat Commun. 2018 Jan 15;9(1):191. doi: 10.1038/s41467-017-02583-0.
MIPF0000130_1
65
/
0
/
65
hsa-miR-513a-5p
MIMAT0002877
3.4e-3
3.4e-3
Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer.
Nat Commun. 2018 Jan 15;9(1):191. doi: 10.1038/s41467-017-02583-0.
MIPF0000130_1
65
/
0
/
65
hsa-miR-513b-5p
MIMAT0005788
9.8e-3
9.8e-3
Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer.
Nat Commun. 2018 Jan 15;9(1):191. doi: 10.1038/s41467-017-02583-0.
MIPF0000130_1
65
/
0
/
65
hsa-miR-513c-5p
MIMAT0005789
1.5e-2
1.5e-2
Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer.
Nat Commun. 2018 Jan 15;9(1):191. doi: 10.1038/s41467-017-02583-0.
MIPF0000130_1
65
/
0
/
65
hsa-miR-514b-5p
MIMAT0015087
2.7e-2
2.7e-2
Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer.
Nat Commun. 2018 Jan 15;9(1):191. doi: 10.1038/s41467-017-02583-0.
MIPF0000130_1
65
/
0
/
65
<
[4]